Allakos Inc (ALLK)
0.76
-0.08
(-9.59%)
USD |
NASDAQ |
Jul 03, 16:00
Allakos Research and Development Expense (Annual): 150.91M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 150.91M |
| December 31, 2022 | 265.08M |
| December 31, 2021 | 196.33M |
| December 31, 2020 | 105.53M |
| Date | Value |
|---|---|
| December 31, 2019 | 61.86M |
| December 31, 2018 | 33.29M |
| December 31, 2017 | 18.51M |
| December 31, 2016 | 14.67M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
61.86M
Minimum
2019
265.08M
Maximum
2022
155.94M
Average
150.91M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Tonix Pharmaceuticals Holding Corp | 86.66M |
| RAPT Therapeutics Inc | 101.00M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 10.33M |